CytomX Therapeutics (CTMX) Short-term Investments (2015 - 2026)

CytomX Therapeutics (CTMX) has 12 years of Short-term Investments data on file, last reported at $317.9 million in Q1 2026.

• Quarterly Short-term Investments rose 884.69% year-over-year to $317.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $317.9 million (up 884.69% YoY) and the FY2025 annual result came in at $124.4 million, up 98.79% from the prior year.
• Short-term Investments rose to $317.9 million in Q1 2026, from $124.4 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $317.9 million in Q1 2026 to a low of $32.3 million in Q1 2025.
• A 5-year average of $120.9 million and a median of $109.2 million in 2025 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2022 — Short-term Investments soared 1984980.0% — and 2025, when it slumped 71.71%.
• Tracing CTMX's Short-term Investments over 5 years: stood at $99.3 million in 2022, then jumped by 58.52% to $157.3 million in 2023, then plunged by 60.23% to $62.6 million in 2024, then soared by 98.79% to $124.4 million in 2025, then jumped by 155.56% to $317.9 million in 2026.
• The last three Short-term Investments figures came in at $317.9 million (Q1 2026), $124.4 million (Q4 2025), and $109.4 million (Q3 2025), per Business Quant data.